Literature DB >> 22063721

Opposing roles of connexin43 in glioma progression.

Wun-Chey Sin1, Sophie Crespin, Marc Mesnil.   

Abstract

Despite the tremendous amount of data over the last 40years, lack of gap junctional intercellular communication (GJIC) or altered expression of gap junction proteins is still a lesser known 'hallmark' of cancer. Expression of astrocytic gap junction protein, connexin43 (Cx43), is often reduced in astrocytomas, the most common neoplasia of the central nervous system (CNS) in adults. Supported by a number of evidences, the global decrease of Cx43 expression appears to be advantageous for the growth of glioma cells. Although the mechanisms by which Cx43 regulates the expression levels of proteins involved in cell growth is unclear, there are evidences to suggest that it might be independent of their channel forming properties. In this regard, the carboxyl tail of Cx43 may have the ability to control the translocation of transcription factor regulators into the nucleus. However, this putative tumor suppressor effect of Cx43 is counterbalanced by its capacity to enhance the migration of glioma cells out of the tumor core through mechanisms that seems to implicate its carboxyl tail, possibly by interacting with the actin cytoskeleton. This ambivalence between the tumor suppressor effect and promotion of cell migration may partly be explained by the heterogeneous expression of Cx43 in the glioma core especially at the malignant glioblastoma stage; some tumor cells would be expected to migrate (Cx43 expressing cells) and others to proliferate (non-expressing Cx43 cells). Moreover, the involvement of Cx43 in glioma progression seems to be more complex since, in addition, GJIC may increase their resistance to apoptosis and Cx43 may also affect cell homeostasis in a paracrine fashion via hemichannel action. In conclusion, Cx43 appears to be involved at different levels of the glioma progression by acting on cell growth regulation, promotion of cell migration and resistance to apoptosis. This article is part of a Special Issue entitled: The Communicating junctions, composition, structure and characteristics.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22063721     DOI: 10.1016/j.bbamem.2011.10.022

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  57 in total

1.  Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.

Authors:  Maria Artesi; Jerome Kroonen; Markus Bredel; Minh Nguyen-Khac; Manuel Deprez; Laurent Schoysman; Christophe Poulet; Arnab Chakravarti; Hyunsoo Kim; Denise Scholtens; Tatjana Seute; Bernard Rogister; Vincent Bours; Pierre A Robe
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

2.  Upregulation of connexin43 contributes to PX-12-induced oxidative cell death.

Authors:  Gang Li; Kun Gao; Yuan Chi; Xiling Zhang; Takahiko Mitsui; Jian Yao; Masayuki Takeda
Journal:  Tumour Biol       Date:  2015-12-18

3.  Density-Dependent Regulation of Glioma Cell Proliferation and Invasion Mediated by miR-9.

Authors:  Mark Katakowski; Nicholas Charteris; Michael Chopp; Evgeniy Khain
Journal:  Cancer Microenviron       Date:  2016-12-14

Review 4.  Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression.

Authors:  Rita Nahta; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Rafaela Andrade-Vieira; Sarah N Bay; Dustin G Brown; Gloria M Calaf; Robert C Castellino; Karine A Cohen-Solal; Annamaria Colacci; Nichola Cruickshanks; Paul Dent; Riccardo Di Fiore; Stefano Forte; Gary S Goldberg; Roslida A Hamid; Harini Krishnan; Dale W Laird; Ahmed Lasfar; Paola A Marignani; Lorenzo Memeo; Chiara Mondello; Christian C Naus; Richard Ponce-Cusi; Jayadev Raju; Debasish Roy; Rabindra Roy; Elizabeth P Ryan; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Renza Vento; Jan Vondráček; Mark Wade; Jordan Woodrick; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  Tunneling nanotubes: A bridge for heterogeneity in glioblastoma and a new therapeutic target?

Authors:  Varun Subramaniam Venkatesh; Emil Lou
Journal:  Cancer Rep (Hoboken)       Date:  2019-05-08

Review 6.  Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.

Authors:  Christina L Grek; Zhi Sheng; Christian C Naus; Wun Chey Sin; Robert G Gourdie; Gautam G Ghatnekar
Journal:  Curr Opin Pharmacol       Date:  2018-05-24       Impact factor: 5.547

Review 7.  Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications.

Authors:  Luc Leybaert; Paul D Lampe; Stefan Dhein; Brenda R Kwak; Peter Ferdinandy; Eric C Beyer; Dale W Laird; Christian C Naus; Colin R Green; Rainer Schulz
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

8.  The advanced development of Cx43 and GAP-43 mediated intercellular networking in IDH1 wildtype diffuse and anaplastic gliomas with lower mitotic rate.

Authors:  Aleksandrs Krigers; Patrizia Moser; Helga Fritsch; Matthias Demetz; Konstantin Brawanski; Claudius Thomé; Christian F Freyschlag
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-26       Impact factor: 4.553

9.  miR-125b inhibits Connexin43 and promotes glioma growth.

Authors:  Zheng Jin; Songbai Xu; Hongquan Yu; Boyu Yang; Hongguang Zhao; Gang Zhao
Journal:  Cell Mol Neurobiol       Date:  2013-09-18       Impact factor: 5.046

Review 10.  A malignant cellular network in gliomas: potential clinical implications.

Authors:  Matthias Osswald; Gergely Solecki; Wolfgang Wick; Frank Winkler
Journal:  Neuro Oncol       Date:  2016-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.